STAT January 24, 2022
Matthew Herper

A group of scientists who did more than perhaps any other to test new treatments for Covid, including establishing that the steroid dexamethasone can save lives, is now turning its focus to the rest of medicine.

The first step, announced today: a partnership with the Paris-based drug giant, Sanofi.

Sanofi will give the U.K. non-profit Protas $6.8 million to begin its work to accelerate how clinical trials are done and make them far cheaper. It aims to build on what the researchers learned studying treatments against Covid-19 to test medicines for heart disease, cancer, depression, Alzheimer’s, and other common ailments.

“One’s got to really think about how one can get better evidence at lower cost in order to get a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article